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ABSTRACT 
 
Multiple myeloma (MM) is a hematological neoplasm that represents about 13% of all 
hematological malignancies. Several evidences have suggested the presence of genetic 
factors able to confer susceptibility to MM.  
The presence of single-nucleotide polymorphisms (SNPs) within the 3’-untranslated 
regions of genes, named miRSNPs, could affect the binding between a microRNA and its 
target, with consequences on gene expression regulation. Considering the important role of 
miRNAs in cancer etiopathogenesis, it is hypothesized here that these miRSNPs could also 
affect the individual risk of MM. 
In this context, we performed a case-control study on MM susceptibility selecting 6 
miRSNPs based on conservation along the evolution, in genes acting in different pathways 
relevant for cancer risk. 
Initially, through a candidate gene approach we selected 52 genes involved in many 
biological functions (apoptosis, B cell differentiation, bone resorption, immunoglobulin 
production) which are deregulated in this neoplastic disease. Within these genes we 
selected the most conserved miRSNPs and evaluated them, in a case-control study, in 
relation to MM susceptibility. The miRSNPs selected for this study were: rs12587 (KRAS), 
rs10434 (VEGFA), rs1126772 (SPP1), rs11047885 (CASC1), rs3024496 (IL10), 
rs12211228 (IRF4).  
The results provides evidence that carriers of the allele A (A/G+A/A) of rs3024496 show 
26% higher risk of developing MM compared to the G/G individuals (OR: 1.26, C.I: 1.09-
1.45, p-value: 0.001) in unadjusted dominant analysis. Moreover, both the heterozygotes 
(AG) and homozygotes (AA) have been associated with and increased risk of MM in 
unadjusted co-dominant model (OR = 1.24; 95% C.I. = 1.07 – 1.45; p-value = 0.004 and 
OR = 1.28; 95% C.I. = 1.09 – 1.51; p-value = 0.002) and a further analysis unveiled the 
presence of a trend both for unadjusted (p-value = 0.0047) and adjusted data (p-value 
=0.0047). 
Thus, we can conclude that genetic variation on miRNA-binding site in IL10 could play an 
important role in etiology of MM cancer, even if further investigation are needed. 
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1. INTRODUCTION 
 
1.1 - MULTIPLE MYELOMA: A GENERAL OVERVIEW 
 
Multiple Myeloma (MM) is the third most frequent hematological neoplasm after leukemia 
and non-Hodgkin’s lymphoma. It is characterized by the clonal proliferation of malignant 
plasma cells in the bone marrow and in the most advanced stages of the disease plasma 
cells can subsequently migrate in extra-medullary districts. 
The mean age at diagnosis is usually around 60 years [1], and the clinical features presented 
by the disease include osteolytic bone lesions, hypercalcemia, renal disease and 
immunodeficiency. 
The worldwide incidence of this neoplasm is around 1.5 new cases every 100,000 people 
per year, while it represents about 1% of all the neoplastic diseases and 13% among the 
hematological malignancies. In Europe the incidence is slightly higher, with 4.6 and 3.2 
new cases every 100,000 people per year, respectively in men and women [2,3].   
Obesity, low vegetable intake, autoimmune diseases, viral infections, exposure to 
pesticides, smoking, alcohol consumption and ionizing radiation have been suggested to 
influence the risk to develop MM, as well as cancer in general, but these data are 
controversial. 
Concerning genetic susceptibility, converging evidences of MM in monozygotic twins and 
familial aggregation of MM and MGUS strongly suggest that MM aetiology has a robust 
genetic component [4,5,6,7]. Genome-wide association studies (GWAS) on MM reported so 
far a total of 8 loci that influence MM risk [8,9,10].  
 
To date, the molecular pathogenetic mechanism that leads to MM is still object of intensive 
investigation.  
In a prospective cohort it was demonstrated that increased levels of a paraprotein named M 
component (or M protein) were detectable in prediagnostic serum samples of all MM cases 
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at least two years prior of MM diagnosis [4,11]. It was thus discovered that MM usually 
evolves from an asymptomatic premalignant stage, the “monoclonal gammopathy of 
undetermined significance” (MGUS), which progresses to smoldering myeloma (SMM) 
and, ultimately, to symptomatic intra- and extramedullary MM at a rate of 1.5% per year 
[12]. 
 
The Mayo Clinic and International Myeloma Working Group (IMWG) have developed 
simplified criteria for the diagnosis of MM, whereby the presence of a spike of M protein 
in the serum higher than 3 g per 100 mL, a urine light-chain protein greater than 1 g per 
day and a proportion of bone marrow plasma cells of 10% or greater have to be met. 
Patients who fulfill these criteria of diagnosis but are asymptomatic are considered to have 
SMM [13].  
 
Extensive molecular, genetic and cytogenetic analyses have uncovered a number of 
chromosomal and genetic abnormalities in MGUS, SMM and MM. In particular, 
hyperdiploidy has been observed in cells in about half of MM patients. Several 
translocations have been described, particularly in non-hyperdiploid patients and around 
75% of them involves the immunoglobulin heavy chain locus [14,15,16,17]. 
 
Until 2005, disease stage was classified according to Durie-Salmon (DS) [18] system. 
However, between 1981 and 2002, data from 10.750 patients with MM from Europe, the 
USA, Canada and Asia were used to formulate the new International Staging System (ISS) 
that has largely replaced the DS system.  
 
 
1.2 - PATHOGENESIS: A MULTISTEP PROCESS 
 
MM is exclusively a post-germinal center tumor that has phenotypic features of long-lived 
plasma cells and is usually distributed at multiple sites in the bone marrow. As in other 
human cancers, increasing evidence indicates that the initiation, relapse and myeloma 
progression are driven by a rare population of cells termed myeloma stem cells [19]. Unlike 
other hematological malignancies, MM is preceded by an asymptomatic age-progressive 
premalignant condition termed “Monoclonal Gammopathy of Undetermined Significance” 
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(MGUS) which progresses to MM or other plasma cells disorders at a rate of 1.5% per year 
[12].  
The estimated prevalence of MGUS is around 4% in men over 50 and increases with aging 
to 5.3% in over 70 and almost 9% in men older than 85. The prevalence in women is 
slightly lower [20,21].  
In a recent study, it has been demonstrated that MM is virtually always preceded by 
MGUS. In a cohort of 77.469 healthy subjects enrolled in the US-wide population-based 
prospective Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial, 71 
developed MM during the course of the study and the M protein was detectable in the 
serum of all MM patients since at least 2 years before of the MM diagnosis [11].  
Therefore, is today universally accepted that MGUS can be considered a pre-malignant 
condition that can evolve to smouldering myeloma (SMM) and ultimately to symptomatic 
intra- and extramedullary MM (Figure 1) [22].  
  
 
Figure 1. Clinical evolution and molecular pathogenesis of MM. The disease arise from a MGUS to a 
smouldering-, intramedullary and extramedullary myeloma and eventually plasma cell leukemia. 
 
The molecular mechanisms that drive the transition from MGUS to MM are still largely 
unclear. The proposed dynamic of the evolution of the MGUS towards the malignant 
phenotype seems to be the result of several overlapping oncogenic events in which specific 
immunophenotypic markers differentiating plasma cells in MGUS, SMM and MM are still 
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lacking. Early cytogenetic changes are seen among almost all patients at the level of 
MGUS [23].  
 
 
1.3 - GENETIC FEATURES 
 
MM plasma cells present severely compromised karyotypes and altered expression patters 
that underline a complex pattern of genetic events. Basing on gains and losses of whole 
chromosomes, chromosomal translocations, transcription profiles and the specific 
expression of cyclin D genes, a molecular characterization of MM genetic subtypes can be 
done.  
One of the events that is universally thought to be of primary importance in onset and 
evolution of MM is represented by a translocation involving the immunoglobulin heavy-
chain (IgH) locus at the 14q32.3 cytogenetic band and, less frequently, the 
immunoglobulin light-chain locus (IgL) at the 2p12 (κ) or 2p11 (λ) loci.  
 
The first molecular classification presented in 1998 by Smadjia et al. proposed the 
distinction between two major classes of patients: hyperdiploid karyotypes (HD), that 
present a number of chromosomes between 48 and 74, and non-hxyperdyploid (NHD) 
karyotypes, that presents less than of 48 or more than 74 chromosomes (also hypodiploid 
MM) [24]. In general, HD MM includes from 50% to 60% of the patients and presents a 
more favorable prognosis.  
 
In the HD subtype trisomies of odd chromosomes are consistently more frequent and 
involve in particular chromosomes 3, 5, 7, 11, 15, 19, 21 [25]. Analysis of expression data 
have shown an overexpression of cyclins D1 (CCND1) and D2 (CCND2) (Figure 2). 
However a clear pathogenetic role of these cyclins in this subgroup is still lacking [26]. 
In the NHD subtype instead, the more frequent genetic abnormality is represented by a 
translocation occurring at the IgH locus. The most frequent translocations reported are 
t(11;14)(q13;q32), t(4;14)(p16.3;q32), t(14;16)(q32;q23) and t(6;14)(p21,q32) [27]. The 
t(11;14)(q13;q32) dysregulates the expression of the CCND1 gene, while the 
t(6;14)(p21,q32) induces the affect the expression of CCND3 gene. The t(4;14)(p16.3;q32) 
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alters the expression of MMSET and FGFR3 genes. The t(14;16)(q32;q23) induces the 
overexpression of the c-MAF [28]. 
 
 
 
Figure 2. Genetic abnormalities subtypes and cyclin dysregulation in MM. About 50-60% of the MM  
presents a HD karyotype, while 40%-50% presents a NHD karyotype. In the HD subgroups expression of 
CCNDs is a common event, while in the NHD subgroup translocations involving the IgH (or rarely (IgL) 
locus are more frequent.  
 
Other common alterations found in the majority of MM patients affect the gain/loss of 
chromosome 1q and the deletion of chromosome 13. Interestingly, both these 
abnormalities have been found in correlation with t(4;14)(p16.3;q32), t(14;16)(q32;q23) in 
NHD MM. When present in HD MM, the 1q gain/loss or the Δ13 deletion distinct 
subgroups associated to a worse prognosis within the HD patients [28].  
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1.4 - miRNAs 
 
microRNAs (miRNAs) are single-stranded non-coding RNA molecules of 22-25 
nucleotides, involved in gene regulation at the post-transcriptional level. Their function is 
to induce degradation of mRNA targets or to inhibit their translation, interacting with the 
3’ untranslated regions (3’UTR) [29,30]. Lin-4 was the first discovered miRNA identified in 
1993 in the nematode Caenorhabditis elegans. It is transcribed into an RNA molecule that 
can repress the expression of lin-14, a protein-coding gene that is relevant to 
developmental timing [31]. In the following years, hundreds of miRNAs were identified in a 
wide range of species, including humans [32,33,34,35]. It was predicted that up to 1000 
miRNAs exist in the human genome [36], and since a single miRNA can bind around 100 
different targets, it has been estimated that miRNAs may regulate up to 30% of the protein-
coding genes [37]. miRNAs are initially transcribed as precursor molecules in the nucleus, 
where they are either organised in genomic clusters or present as individual genes. It has 
been reported that miRNA genes could be located within exons or introns of non-coding 
genes [38], as well as in protein-coding genes [39]. The RNA polymerase II transcribes a long 
primary RNAs (pri-miRNAs) in the nucleus [40] . Then, pri-miRNAs are processed by 
Drosha, a member of the RNase III enzyme family, into precursors (pre-miRNAs) of 70 
nucleotides in length with a stem-loop structure [41]. Pre-miRNAs are exported from the 
nucleus to the cytoplasm by the exportin-5 where they are processed by another RNase III 
enzyme, Dicer. This causes the release of a double-stranded RNA duplex of 22 nucleotides 
that is incorporated into the RNA-induced silencing complex [42]. In this complex, one 
strand is retained as the mature miRNA, whereas the other strand is generally degraded. 
The mature miRNA binds the 3’-UTR of target mRNAs through imperfect base pairing [43]. 
Perfectly matched sequence complementarity is required only between the “seed” region of 
the miRNA (nucleotides 2-7 of mature sequence) and the target mRNA [44]. Such binding 
leads to degradation, destabilisation or translational inhibition of the mRNA and 
consequently silencing gene expression [45]. Since the binding between miRNA and target 
mRNA does not require perfect complementarity, a single miRNA can affect a broad range 
of mRNAs and consequently the whole miRNA family possesses the potential to target and 
regulate thousands of genes [46,47,48]. Approximately one-third of the protein-coding genes 
are controlled by miRNAs; thus, almost all cellular pathways are directly or indirectly 
 11 
 
Identification of polymorphic miRNA-binding sites associated with the risk of multiple myeloma 
 
influenced by miRNAs. miRNAs are involved in cell proliferation, cell differentiation [49], 
apoptosis [50] and metabolism [51]. Moreover, recent studies have shown that miRNAs 
participate in human carcinogenesis as tumour suppressors or oncogenes [52,53,54]. In cancer, 
an aberrant miRNA expression and/or function is frequently observed [52,55,56]. 
Furthermore, as miRNA expression patterns strongly correlate with tumour type and stage 
[57,58], miRNAs can be used as clinical markers for cancer diagnosis and prognosis [59,60].  
 
 
1.5 - miRNA: ROLE IN THE PATHOGENESIS OF MM 
 
Studies showed that miRNAs are deregulated also in cancer and that they have important 
roles in the pathogenesis and/or malignant progression of solid and hematological 
malignancies. miRNAs involved in carcinogenesis are classified into: 
 
 Oncogenic miRNAs (oncomiRs). They are up-regulating miRNAs that play a 
positive role in the development of cancer because they determine the inhibition of 
tumor suppressor genes.  
 
 Tumor suppressor miRNAs (tumor suppressor miRs). These miRNAs normally 
inhibiting cell proliferation thus their down-regulation favor cancer development 
[61,62].  
 
In the last 4 years, several studies investigated the role of miRNAs in the pathogenesis of 
MM [63]. In particular, an over-expression of miR-21 in MM and MGUS blood samples was 
observed [64,65]. Moreover, Lionetti et al showed a deregulation of 16 miRNAs mapped to 
chromosomal regions frequently involved in allelic imbalances found in MM cell lines [66]. 
In another study, an altered expression of miR-15a/16-1 cluster at 13q14 was shown [67]. 
Furthermore, 32 intragenic miRNAs were found de-regulated in MM including miR-152, 
miR-335, and miR-342-3p within COPZ2, MEST, and EVL respectively, all known genes 
altered in MM [66,67]. Since MM is characterized by very complex cytogenetic aberrations 
that affects prognosis and molecular profiling [68], it is likely that these aberrations might 
also affect miRNA expression. For example, up-regulation of miR-1 and miR-133a was 
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found to be related to t(14;16) in MM cases [69]. miRNA deregulation by epigenetic 
mechanisms (such as promoter hyper-methylation and/or histone hypo-acetylation), and by 
other miRNAs were also described. In Table 1 [64], deregulated miRNAs are shown with 
their associated target genes, commonly involved in MM.  
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
Table 1. miRNA deregulated in specific cytogenetic aberrations in multiple myeloma. 
 
 
1.6 - STUDY OF SINGLE NUCLEOTIDE POLYMORPHISMS IN MULTIPLE 
MYELOMA RISK 
 
Some evidences suggested the presence of genetic factors involved in MM pathogenesis. 
The first evidence of familiarity in MM is from 1925 and has been followed in the years by 
several case reports and case-control studies [70-75]. Recently, familial MM studies on larger 
population-based cohorts have been conducted and several interesting findings have arisen. 
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In a population-based case-control study exploring 8,406 MM diagnosed in Sweden 
between 1958 and 1998 and 22,490 first-degree relatives of the MM cases it was found that 
MM relatives had a 1.7-fold significantly increased risk to develop MM with respect to 
first-degree relatives of controls (RR= 1.67; 95% C.I.:1.02 – 2.73). In addition, in contrast 
with the general population, familial MM risk was higher among female relatives 
(RR=3.74; 95% C.I.: 1.58-8.83) [76]. In the same study, the risk to develop MGUS in 
relatives of MM cases was found to be not significant. In a second larger case-control 
study done in the Swedish population, a total of 13,896 MM patients and 37,838 first-
degree relatives was used to estimate the risk of developing other hematological 
malignancies, MGUS and solid tumors. Compared to first-degree relatives of controls, MM 
relatives had an increased risk to develop both MM (RR= 2.1; 95% C.I.: 1.6-2.9) and 
MGUS (RR= 2.1; 95% C.I.: 1.5-3.1), and also other malignancies (ALL, solid tumors and 
bladder cancer) [5]. To date, only one large study explored the familiarity of MGUS in a 
case-control study on 4.458 MGUS patients and 14.621 first-degree relatives. Among 
relatives of MGUS patients the risk to develop both MGUS (RR=2.8; 95% C.I.: 1.4-5.6) 
and MM (RR=2.9; 95% C.I.: 1.9-4.3) was increased respect to the relatives of the controls 
[77].  
 
Taken together, all this information supports the hypothesis that genetic factors could play 
a key role in increasing the susceptibility to both MGUS and MM. Considering that MGUS 
is a pre-symptomatic conditions that always precedes MM, these findings add a strong 
rationale to the research of genetic factors able to modify the risk to develop these 
conditions. Among the genetic variability, Single Nucleotide Polymorphisms (SNPs) are 
the most frequent source of variations in human genomes and have been largely 
investigated as risk factors in many types of cancers and other diseases.  
In the last ten years several studies, conducted with a candidate gene approach, have 
identified SNPs, involved in various pathways and processes, associated with the disease 
susceptibility. However, these studies were conducted on small size samples and thus only 
few of them were validated in independent studies [78]. 
 
The first genome-wide association study (GWAS) of MM based on a meta-analysis of 
German and UK datasets reported that variation at 2p23.3 (rs6746082), 7p15.3 
(rs4487645) and 3p22.1 (rs1052501) influences MM risk [8]. To validate these findings, a 
case-control association study was carried out in 1,139 MM patients and 1,352 healthy 
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controls belonging to the IMMEnSE consortium and the associations were confirmed 
(rs4487645 was found the most strongly associated with an Odds Ratio=1.37, 95% 
confidence interval: 1.21-1.56; p=7.96x10-7, p-trend=2.00x10-4). In the meta-analysis, 
combining the GWAS with the confirmatory study, all the three polymorphisms reached 
the genome wide significance level (p<10-7). This replication provides a convincing 
evidence of the role of common genetic variations at 7p15.3, 3p22.1, and 2p23.3 genetic 
loci in the MM risk [79]. 
Furthermore 3q26.2 (rs10936599), 6p21.33 (rs2285803), 17p11.2 (rs4273077) and 22q13.1 
(rs877529) have been found significantly associated with multiple myeloma in GWAS 
which counted 4,692 MM cases and 10,990 controls [10]. 
 
In a meta-analysis of two GWAS of multiple myeloma including a total of 1,661 affected 
individuals, risk for developing a specific tumor karyotype was investigated. The 
t(11;14)(q13;q32) translocation was strongly associated with SNP 870 G>A, which maps 
CCND1, causing overexpression and supporting an uncontrollable cellular growth [9].  
 
A modest but significant increase risk of multiple myeloma was associated with SNPs at 
2p23.3 (rs6746082), 3p22.1 (rs1052501), 3q26.2 (rs10936599), 6p21.33 (rs2285803), 
7p15.3 (rs4487645), 17p11.2 (rs4273077) and 22q13.1 (rs877529) between individuals 
with MGUS [8,10]. However, with the aim to confirm these findings, a following study, with 
492 cases of MGUS and 7306 controls, was carried out. The findings highlighted that only 
rs1052501, rs2285803, rs4487645, rs4273077 kept significant associations with the disease 
[80]. 
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2. AIM AND SCOPE 
 
The main aim of this work was to investigate and highlight the role of miRSNPs in 
modifying the individual risk to develop MM. The study focused on miRSNPs located in 
genes that act in several biological processes known to be relevant in MM pathogenesis: 
apoptosis, B cell differentiation, bone resorption, immunoglobulin production.  
Target genes have been chosen following a candidate gene approach and miRSNPs have 
been selected in silico for conservation along the genomes of several species. Moreover, 
the best conserved miRSNPs have been evaluated for their ability to affect the binding of 
the miRNA with its target, by assessing the variation of Gibbs free energy between the two 
alleles of each SNP.  
After that, these SNPs were tested in a case-control study to evaluate if they could 
influence the individual genetic susceptibility to MM. 
 
The secondary goals of this line of research are to detect novel important miRNAs for the 
development of MM, identify novel key-genes involved in MM and shed light into the 
mechanisms of MM pathogenesis. 
 
As long term goals there will be the possibility to use the information gained by our work 
for the identification of markers useful for diagnosis or prognosis. Optimistically, the 
information could be important for the characterization of targets for novel therapeutic 
approaches. 
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3. MATERIALS AND METHODS 
 
3.1 – IMMEnSE CONSORTIUM 
 
In this case-control study we analyzed samples belonging to the International Multiple 
Myeloma rESEarch (IMMEnSE) consortium.  
 
The IMMEnSE consortium is organized on the basis of common criteria used in other 
international cohorts and consortia. It is constituted by several research groups operating in 
the field of hematology, molecular genetics and epidemiology of MM. 
Aim of the IMMEnSE consortium is to contribute to the understanding of factors that 
influence risk of MM, response to treatment and survival. The IMMEnSE consortium is 
oriented towards a knowledge and data sharing policy. In other words, expertise and 
structure of different groups are available for all proposals and the projects presented by 
the member groups about research on genetics, pharmacogenetics and biomarkers for 
treatment outcome and overall survival. 
With this aim, MM cases have been recruited together with several clinical variables, 
offering the opportunity to build one of the largest international data- and bio-bank about 
this cancer. Controls from the general population have been selected as well to perform 
case-control association studies. Biological samples and clinical information on the MM 
cases are constantly collected and stored with the aim to build a unique and complete 
databank. 
Participating groups/centers that has contributed with samples and data of cases and 
controls are shown in Figure 3 and Table 2. 
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Figure 3. Centers participating in the IMMEnSE consortium. 
 
 
Center Region P.I. 
German Cancer Research Center 
Genomic Epidemiology Group 
Heidelberg 
Germany (DE) 
Dr. Federico Canzian 
f.canzian@dkfz.de 
Pisa University Hospital 
Dept. of Oncology, Transplants 
and Advanced Technologies, 
Section of Hematology 
Pisa 
Italy (IT) 
Dr. Gabriele Buda 
Ga.buda@libero.it 
Medical University of Lodz 
Dept. of Hematology 
Lodz 
Poland (PL) 
Dr. Kryzstof Jamroziak 
Krzysztof.jamroziak@wp.pl 
Cracow University Hospital 
Department of Hematology 
Cracow 
Poland (PL) 
Dr. Artur Jurczyszyn 
mmjurczy@cyf-kr.edu.pl 
Rzeszow Regional Hospital 
Department of Hematology 
Rzeszow 
Poland (PL) 
Dr. Marek Dudzinski 
marekdudzi@gmail.com 
Holycross Cancer Center 
Hematological Department 
Kielce 
Poland (PL) 
Dr. Marzena Watek 
Marzena.watek@wp.pl 
 
Hospital Universitario Virgen de 
las Nieves, 
GENYO 
 
Granada 
Spain (ES) 
 
Dr. Juan Sainz Perez 
Juan.sainz@genyo.es 
Hospital Universitario de 
Salamanca 
Servicio de Hematologia 
Salamanca 
Spain (ES) 
Dr. Ramon Garcia-Sanz 
rgarcias@usal.es 
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Table 2. Centers participating and reference person for each center. 
 
The biological bank for all samples made available to the consortium was established at 
German Cancer Research Center (DKFZ) of Heidelberg, Germany, where genetic analysis 
have been conducted. The Genomic Epidemiology Group at the German Cancer Research 
Center, led by Dr. Federico Canzian, is in charge to coordinate the collection and the 
storage of both samples and data. 
From each participating center, native genomic DNA of MM cases (1 µg with a minimum 
concentration of 10 ng/µl) and controls was collected. When available, an aliquot of whole 
blood has been isolated in EDTA tubes (at least 1ml) and stored at -20°C. In order to 
ensure enough material for each genotyping, DNA from some samples was amplified with 
whole genome amplification procedure. 
 
The physicians in charge for the patients had the responsibility of sending to the central 
IMMEnSE database anonymized identity codes for each patients. Only the physician 
Hospital Doce de Octubre 
Hematological department 
Madrid 
Spain (ES) 
Dr. Joaquin Martinez 
jmartinezlo@hematologia12octubre.com 
Hospital Moraes Meseguer 
Hematology department 
Murcia 
Spain (ES) 
Dr. Felipe de Arriba de la Fuente 
farriba@um.es 
Hospices Civils of Lyon 
Lyon 
France (FR) 
Dr. Charles Dumontet 
Charles.dumontet@chu-lyon.fr 
Hospital de Braga 
University of Minho 
Braga 
Portugal (PT) 
Dr. Rui Manuel reis 
rreis@ecsaude.uminho.pt 
Sammelweis University 
Department of Internal Medicine 
Budapest 
Hungary (HU) 
Dr. Judit Varkonyi 
varkjud@kut.sote.hu 
Roskilde Hospital, Copenhagen 
University 
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responsible for the biological material collection knew the patient identity. All the 
subsequent analyses was referred to the anonymous code. 
Clinical variables concerning therapy and the individual response, progression free 
survival (PFS) as well as patients overall survival (OS) and toxicity events have been 
collected as well to investigate the role of genetic variants in the pharmacogenetics of MM. 
Primary data (covariates provided by the collaborating centers) was stored in the central 
IMMEnSE database, which was maintained at the Genomic Epidemiology Group of 
DKFZ. DKFZ staff involved in the project have responsibility for the security of the 
IMMEnSE database. 
 
 
3.2 -  STUDY POPULATION 
 
The IMMEnSE consortium has been started in June 2010 and counts to date samples and 
data of over 2.400 cases and 3.600 controls (Table 3). 
Cases were defined by a confirmed diagnosis of MM, according to the International 
Myeloma Working Group (IMWG) criteria. For each patient, information about clinical 
features at diagnosis are collected (see table on clinical information – Table 4). 
Controls were selected among the general population as well as hospitalized subjects with 
different diagnoses excluding cancer. 
For each subject, informed consent to collect fresh blood and perform DNA extraction for 
research purpose was requested and collected individually by each center. The study has 
been approved by the relevant ethical committees. 
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Country Cases 
Median age 
(5th-95th 
percentile) 
Controls 
Median age 
(5th-95th 
percentile) 
Control type 
Italy 288 63 (46–78) 305 59 (42-76) 
General 
populations 
Poland 458 63 (42-82) 267 68 (43-79) Blood donors 
Spain 378 64 (46-82) 1199 66 (43-84) 
Hospitalized 
subjects 
France 149 57 (37-68) 259 48 (18-63) Blood donors 
Portugal 126 68 (45 – 82) 168 58 (53-79) Blood donors 
Hungary 205 68 (34-90) 172 74 (55-87) 
Hospitalized 
subjects 
Denmark 405 56 (43-65) 1067 63 (52-73) Blood donors 
Israel 166 60 (41-77) 163 - Blood donors 
Canada 118 58 (42-70) - - - 
Japan 107 66 (47-84) - - - 
Total 2.400 63 (37-84) 3.600 63 (18-92)  
Table 3. MM cases and healthy controls collected in the IMMEnSE consortium. 
 
 
 
Variable NAME 
TYPE OF 
VAL 
FORMAT DESCRIPTION 
ID
 
IMMEnSE ID 
Univocal 
Code 
9 digit code 
Univocal sample ID given to all the IMMEnSE samples. This ID 
contains info about the region, the center and a proghressive number 
that identify the samples. 
Original ID 
Univocal 
code 
Variable ID of the samples in original files or plate maps. 
D
em
o
g
ra
p
h
ic
al
 a
n
d
 d
ia
g
n
o
si
s 
in
fo
 
DATE OF BIRTH Date GG/MM/YYYY Date of birth of the patient (GG/MM/YYYY) 
YEAR OF BIRTH Numeric YYYY Year of birth of the patient (YYYY) 
DATE OF 
DIAGNOSIS 
Date GG/MM/YYYY Date of first 
YEAR OF 
DIAGNOSIS 
Numeric YYYY Year of diagnosis of the patient (YYYY) 
AGE AT 
DIAGNOSIS 
Numeric Number Age of diagnosis (calculated as Year at diagnosis – year of birth) 
SEX (1M, 2F) Binary 1,2 1=Male, 2=Female 
PREVIOUS MGUS 
(YES/NO/UNKN) 
Binary 0, 1, 9 0=No history of MGUS/1=previously MGUS/9=unknown 
MM STAGE 
(Durie-Salmon) 
Numeric 1 , 2, 3 + A or B Durie-Salmon stage (1A, 1B, 2A, 2B, 3A, 3B) 
SEROTYPE MM Text Ig + subtype 
Ig serotype of MM (IgA, IgG, IgM, LCL and LCK = light chain lambda 
or kappa, NS= non secretory) 
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B2M Numeric µg/L Beta-2-microglobulin value at diagnosis (micrograms/liters) 
Hb Numeric mg/dL Haemoglobin value at diagnosis (decigrams/deciliters) 
CREAT Numeric mg/dL Creatinin value at diagnosis (decigrams/deciliters) 
ALB Numeric g/dL Albumin value at diagnosis (grams/milliliters) 
CALCIUM Numeric mmol/L Calcium value at diagnosis (millimoles/liters) 
BONE LESIONS Binary 1, 0 1=present, 0=absent, 9=unknown 
T
re
at
m
en
ts
 
DATE 
TREATMENTS 
STARTED 
Date GG/MM/YYYY Date in which the treatment of the patients started 
FIRST LINE 
THERAPY 
Text Letters code 
First treatment received by the patients (DAV, TALDEX, MP, MPT, 
VELDEX…) 
RESPONSE TO 1^ 
LINE 
Text CR, PR, SD, PD 
Response to first line therapy (codified as: CR=complete remission, 
PR= partial remission, SD=stable disease, PD=progressive disease) 
SECOND LINE 
THERAPY 
Text Letters code 
In the case that the patients received a second line before ASCT, insert 
here the second line therapy (DAV, TALDEX, MP, MPT, VELDEX..) 
RESPONSE TO 2^ 
LINE 
Text CR, PR, SD, PD 
Response to second line therapy (codified as: CR=complete remission, 
PR= partial remission, SD=stable disease, PD=progressive disease) 
THIRD LINE 
THERAPY 
Text  
In the case that the patients received a second line before ASCT, insert 
here the third line therapy (DAV, TALDEX, MP, MPT, VELDEX..) 
RESPONSE TO 3^ 
LINE 
Text CR, PR, SD, PD 
Response to third line therapy (codified as: CR=complete remission, 
PR= partial remission, SD=stable disease, PD=progressive disease) 
A
u
to
-S
C
T
 
1st AutoSCT (Yes/No) Binary 1, 0 AutoSCT (1=yes, 0=no) 
RESPONSE TO 1st 
ASCT 
Text CR, PR, SD, PD 
Response to first line ASCT (codified as: CR=complete remission, PR= 
partial remission, SD=stable disease, PD=progressive disease) 
DATE 1st ASCT date GG/MM/YYYY Date of ASCT 
2nd AutoSCT 
(Yes/No) 
Binary 1, 0 Second AutoSCT (1=yes, 0=no) for patients that did it 
RESPONSE TO 2nd 
ASCT 
Text CR, PR, SD, PD 
Response to second ASCT (codified as: CR=complete remission, PR= 
partial remission, SD=stable disease, PD=progressive disease) 
DATE 2nd ASCT Date GG/MM/YYYY Date of 2nd ASCT 
OVERALL ASCT 
RESPONSE 
binary CR, PR, SD, PD 
Global evaluation of the response to ASCT treatment (codified as: 
CR=complete remission, PR= partial remission, SD=stable disease, 
PD=progressive disease) 
MAINTENANCE 
THERAPY 
text Letter code Maintenance therapy after ASCT or first line treatment 
P
ro
g
re
ss
io
n
 i
n
fo
 
DATE PFS START Date GG/MM/YYYY 
Date from which start to calculate PFS (generally, data of first 
treatment) 
DATE OF 
PROGRESSION (PFS 
END) 
Date GG/MM/YYYY Date of progression of the disease (Relapse) 
PROGRESSION 
(Yes/No) 
Binary 1, 0, 9 0=no progression, 1=progression, 9=unknown 
PFS Numeric Months Time without progression, in months 
THERAPY AT 
RELAPSE 
text Letters code 
Treatment received at relapse (DAV, TALDEX, MP, MPT, 
VELDEX..) 
RESPONSE TO 
THERAPY 
Text CR, PR, SD, PD 
Response to treatment after relapse (codified as: CR=complete 
remission, PR= partial remission, SD=stable disease, PD=progressive 
disease) 
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Table 4. Clinical information collected in the IMMEnSE database. Complete remission (CR) was defined as 
the disappearance of the M-component from both serum and urine, and <5% plasma cells in bone marrow. 
Patients were defined as in partial remission (PR) when the initial monoclonal protein value was reduced to 
<50% with the stability of lytic bone lesions. Stable disease (SD) was defined as the failure to achieve either 
CR or PR. Progressive disease (PD) required at least a 25% increase in paraprotein. Progression Free 
Survival (PFS) indicate the amount of months without disease from the date of transplantation (the second for 
patients that obtained a tandem transplantation) to progression. Overall Survival (OS) is defined as the time 
from the diagnosis to death, or last follow-up. 
 
Our case-control study was carried out in 3,117 cases and 1,960 healthy controls coming 
from different geographical regions. Patients’ median age at diagnosis was 62 (range, 55-
68 years). Clinical stage at diagnosis was determined in accordance to clinical staging 
system described by Durie & Salmon [19]. Healthy subjects (N=1,960) with a median age of 
52 (range, 41- 64 years) and with a similar distribution between genders as MM cases were 
collected. The clinical characteristics of MM patients and of healthy controls are listed in 
Table 5. 
 
 Cases Controls Total 
Median age 
(25%-75% percentiles) 
62 (55-68) 52 (41-64) 
 
Gender    
Males 1.612 1.019 2.631 
Females 1.505 941 2.446 
DATE OF THERAPY 
AT RELAPSE 
date GG/MM/YYYY Date of starting of the therapy at relapse 
F
o
ll
o
w
 u
p
 
LAST FOLLOW UP date GG/MM/YYYY Date of the last observation of the patients 
DATE OF DEATH date GG/MM/YYYY Date of birth 
ACTUAL STATUS Text DEAD, ALIVE Dead/ Alive/ Relapsed/ Unknown 
DEAD (Yes/No) Binary 1, 0, 9 0=alive, 1=dead, 9=unknown 
DATA IN Date GG/MM/YYYY 
Date from which start to calculate OS (generally, data at diagnosis or 
date of first treatment) 
DATE OS Date GG/MM/YYYY Date of end observation for OS (last control or death) 
OS numeric months Overall survival, in months 
N
o
te
s 
NOTEs on PFS Text Text Relevant note for PFS calculation/evaluation 
General NOTEs Text Text General notes on the patient 
CARYOTYPE Text Text Caryotype and molecular alteration 
CYTOGENETICS Text Text 
Cytogenetic alterations in patient’s plasma cells (i.e. Translocations 
and deletions) 
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Geographic origin    
Denmark 
299 
9.59% 
489 
24.95% 
788 
France 
502 
16.11% 
176 
8.98% 
678 
Hungary 
155 
4.97% 
101 
5.15% 
256 
Israel 
108 
3.46% 
97 
4.95% 
205 
Italy 
298 
9.56% 
228 
11.63% 
526 
Poland 
1.259 
40.39% 
350 
17.86% 
1.609 
Portugal 
152 
4.88% 
195 
9.95% 
347 
Spain 283 
9.08% 
324 
16.53% 
607 
Canada 61 
1.96% 
0 
0.00% 
61 
Total 3,117 
100% 
1,960 
100% 
5.077 
Table 5. Characteristics and distributions of cases and controls. 
 
 
3.3 - SELECTION OF CANDIDATE GENES 
 
We complied the list of candidate genes through both literature search and bioinformatics 
data mining approach. In particular, three search-tools were used: Coremine, SNPs3d and 
Gene Prospector.  
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3.3.1 – COREMINE 
 
Coremine Medical (http://www.coremine.com/medical/#search) is a product of the 
PubGene Company designed to seeking information in biomedical literature. 
Coremine performs text-mining searches about a disease of interest using biomedical 
abstracts published in PubMed and presents search results as a graphic network that 
describes relationships discovered among published papers. The network is also a 
navigational tool that can help searchers explore concepts related to their search term. 
Coremine Medical uses the approach to show relationships between a huge range of 
biomedical terms, including Medical Subject Heading, Gene Ontology, Pharmaceutical, 
Herbal medicine and Chemical as well as Gene and Protein terms. The text records 
indexed are those comprising the MEDLINE database that contains more than 22 million 
references to journal articles in life sciences with a concentration on biomedicine (i.e. titles 
and abstracts contained in PubMed). In fact, MEDLINE is the primary component of 
PubMed. 
Coremine search results include documents and resources that discuss the disease, as well 
as networks and lists that show how the query concept is related to other bio-medical 
concepts (other diseases, drugs, genes).  
For our purpose through this tool we were able to extract genes involved in MM cancer 
cited in MM scientific publications. We crossed the information obtained between MM 
and a set of biological processes:  
 Apoptosis  
 B cell differentiation  
 Bone resorption  
 Immunoglobulin production  
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We obtained thus a list of 16.793 genes involved in these biological processes which are 
known to contribute to the development of cancer in general and of MM in particular, as 
detailed in Table 6. 
 
BIOLOGICAL PROCESSES NUMBER OF GENES INVOLVED 
Apoptosis 8,763 
B cell differentiation 2,509 
Bone resorption 2,855 
Immunoglobulin production 2,666 
Table 6. Genes involved both in MM and selected biological processes. 
 
 
3.3.2 - SNPs3d 
 
Also this website tool (http://www.snps3d.org/) has been designed to allow to seek any 
kind of desired information in biomedical literature using a simple text mining method [81].  
SNPs3d generates lists of candidate genes for any specified disease, based on an analysis 
of the relationship between the disease and genes, as reflected in the literature.  
The identification of candidate genes makes use of simple text mining techniques. Concept 
profiles are constructed for each disease and for each gene. Each concept (a disease or a 
gene) is represented by an ordered list of words and terms most closely associated with the 
concept. The set of words and terms is compiled from the contents of the approximately 
80,000 PubMed abstracts that have been manually associated with one or more human 
genes in the NCBI Entrez Gene database. 
 
In this case, the candidate gene list was obtained using “Multiple Myeloma” as query.  
The findings that SNPs3d provided us, in according with scientific bio-medical 
documentation, showed that 316 genes were involved in MM pathogenesis. 
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3.3.3 – GENE PROSPECTOR 
 
The Gene Prospector (http://www.hugenavigator.net/HuGE Navigator/geneProspector 
StartPage.do) is one component of the HuGE Navigator, an integrated, searchable 
knowledge base of genetic associations and related information in human genome 
epidemiology. HuGE Navigator provides access to a continuously updated knowledge base 
in human genome epidemiology, including information on population prevalence of 
genetic variants, gene-disease associations, gene-gene and gene-environment interactions, 
and evaluation of genetic tests. 
 
The Gene Prospector is a bioinformatics tool designed to sort, rank, and display 
information about genes in relation to human diseases, risk factors and other phenotypes 
[82]. This tool uses a database made of articles and genes from the National Center for 
Bioinformatics (NCBI) Entrez Gene database. The database has indexed more than 30,000 
articles, referencing more than 3,000 genes and nearly 2,000 disease terms. Links are 
provided to evidence from published literature and to other online data sources. 
 
In Gene Prospector output genes were ranked by the strength of evidence calculated on the 
basis of the volume of different types of published literature in human genome 
epidemiology (data source: HuGE Literature Finder) and possible research being done on 
two animal models (rat and mouse) (data source: NCBI Entrez Gene database, 
http://www.ncbi.nlm.nih.gov/gene). HuGE Literature Finder is a search engine for finding 
published literature on genetic associations and other human genome epidemiology. The 
search query can include disease/outcome, environmental factors, genes, author's name, 
affiliation, etc. The results can be further refined by the filtering feature.  
 
As in other cases previously mentioned, also for this data meaning research we needed, as 
query concept the disease name for obtain, thanks to scientific literature published so far, 
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all genes involved in the pathogenesis of it. So that this text mining strategies about MM 
provided us 212 genes. 
 
 
3.3.4 - DIFFERENCES BETWEEN COREMINE, SNPs3d AND GENE 
PROSPECTOR 
 
All these website-tools make the same bioinformatics work, but with different data mining 
results. The reason of that is caused by the fact that these algorithms presented database 
with different sizes. In fact, SNPs3d and GENE PROSPECTOR database have been 
created manually as they indexed, respectively, more than 80.000 (data updated of October 
2005) and 30.000 (data updated of November 2007) PubMed abstracts. Therefore, these 
databases need to be continually updated. 
Instead, COREMINE have been linked directly to MEDLINE database (it is also the 
PubMed database) which contains more than 22 million references. The advantage of 
COREMINE tool is that it does not need to continuous updates because it is update in real 
time. 
 
 
3.3.5 – FINAL CANDIDATE GENE LIST 
 
By running the algorithms described above, a set of genes were found implicated in MM.  
We conducted a further analysis to find the genes that were in common with all sets, in 
other words, we did the intersection of the results provide by Coremine, SNPs3d and Gene 
Prospector. 
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For this purpose we used an algorithm based on Venn Diagram 
(http://www.bioinformatics.lu/venn.php) that was able to find the elements in common 
between two or three data sets. 
With this algorithm we found 52 genes in common with the output of the software 
previously mentioned. These 52 genes were selected as candidates for our study (Table 7).   
 
Gene Symbol position 
ABCB1 7q21.12 
ABCG2 4q22.1 
CASP8 2q33.1 
CD27 12p13.31 
CD28 2q33.2 
CD4 12p13.31 
CD40 20q13.12 
CD70 19p13.3 
CD79B 17q23.3 
CDKN2A 9p21.3 
CFLAR 2q33.1 
COL18A1 21q22.3 
CXCL12 10q11.1 
FAS 10q24.1 
FASLG 1q23 
GSTP1 11q13 
ICAM1 19p13.3-p13.2 
IL10 1q31-q32 
IL13 5q31 
IL1B 2q14 
IL4 5q31.1 
IL5 5q31.1 
IL6 7p21 
IL6R 1q21 
IL6ST 5q11 
IL8 4q13-q21 
IRF4 6p25-23 
KRAS 12p12.1 
LIG4 13q33-q34 
NFKB1 4q24 
NFKB2 10q24 
NFKBIA 10q13 
NOTCH1 9q34.3 
SPP1 4q21-q25 
TERT 5p15.33 
TGFB1 19q13.2 
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TLR10 4p14 
TNF 6p21.3 
TNFRSF10C 8p22-p21 
TNFRSF10D 8p21 
TNFRSF11A 18q22.1 
TNFRSF11B 8q24 
TNFRSF13B 17p11.2 
TNFRSF13C 22q13.1-q13.31 
TNFRSF17 16p13.1 
TNFSF10 3q26 
TNFSF13B 13q32-q34 
TNFSF8 9q33 
TP53 17p13.1 
TRAF3 14q32.32 
VCAM1 1p32-p31 
VEGFA 6p12 
Table 7. Physical location of candidate genes on the genome. 
 
 
3.4 – SELECTION OF POLYMORPHISMS 
 
Next, we analyzed the 52 candidate genes to search the polymorphisms which could alter 
the mechanism of the regulation of gene expression conducted by miRNA and that could 
contribute to the development of MM. 
 
Putative miRNA-binding sites within the 3’UTR (defined as transcribed sequences from 
the stop codon to the end of the last exon of each gene) were detected by jSNPSelector 
(http://sourceforge.net/projects/jsnpselector/), a special experimental algorithm designed 
by collaboration between the Departments of Biology and Informatics in the University of 
Pisa that interrogates the ENSEMBL database.  
 
The miRSNPs search was performed choosing a series of criteria, including: 
 The specific population where to search for polymorphisms. For this study the 
search was conducted on the Caucasian population. 
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 The choice of the allele frequencies. As minor allele frequency (MAF) we selected 
0.16 (16%), given that a too low allele frequency does not provide the needed 
statistical power for the study. 
 The region of genes where to search for polymorphisms. In our case, obviously, the 
3’UTR region was chosen.  
 The choice of Genomic Evolutionary Rate Profiling (GERP) conservation score used 
as filter to choose the miRSNPs with the highest conservation along the evolution. 
Such GERP conservation score was computed by ENSEMBL by aligning of the 
genomes of 35 eutherian mammals. For this study the polymorphisms selected had a 
GERP conservation score higher than 1. 
 
Thus, we obtained a list of 17 miRSNPs (Table 8), fulfilling the above criteria. These 
miRSNPs belong to 9 candidate genes for MM. 
 
To be sure that these miRSNPs, provided by jSNPSelector, were truly located within 
3’UTRs of the selected genes we have done a further check on dbSNP database 
(http://www.ncbi.nlm.nih.gov/SNP/).  
 
GENE dBSNP ID 
ANCESTRAL 
ALLELE 
VARIANT 
ALLELE 
CONSERVATION 
SCORE 
TNFSF8 rs3181374 A G 3.72 
IRF4 rs12211228 G C 2.78 
VEGFA rs3025053 G A 2.57 
TNFRSF13C rs7290134 T C 2.4 
IL10 rs3024496 C T 1.74 
KRAS rs7973623 G A 1.64 
SPP1 rs1126772 A G 1.48 
TNFRSF10D rs7957 A G 1.48 
VEGFA rs10434 G A 1.37 
TNFSF8 rs1126711 T C 1.31 
TNFSF8 rs3181372 T C 1.30 
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IRF4 rs1050976 T C 0.988 
IRF4 rs9392502 C G 0.871 
KRAS rs7973450 T C 0.563 
IRF4 rs7768807 T C 0.283 
KRAS rs12587 C A 0.111 
COL18A1 rs7499 G A 0.0436 
Table 8. miRSNPs highly conserved located in 3’UTR sites, sorted by conservation score. 
 
 
3.5 – PRIORITIZATION OF miRSNPs 
 
All the collected miRSNPs have been prioritized in silico according to their conservation 
score. That means, if one nucleotide is very conserved inside a specific gene along the 
evolution it should be very important for the good function of the correlated protein and, in 
the last analysis, for the whole cell where the respective gene is expressed. 
In order to select the best miRSNPs, we verified the conservation property with another 
algorithm: Haploreg (http://www.broadinstitute.org/mammals/hap loreg/haploreg.php). 
The prioritization of miRSNPs was made with more than one algorithm with the aim to 
reduce the risk of artifacts caused by the uncertainty related to the reliability of 
jSNPSelector algorithm. Through Haploreg we have selected the most conserved 
miRSNPs according to two conservation scores: GERP and SiPhy-omega. Both these 
scores were designed to detect constrained sequences across mammalian genomes.  
 
By the intersection of the results obtained through these tools, we have chosen 6 miRSNPs 
located in the 3’ UTR of 6 different genes. All the details are shown in Table 9. 
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ID GENE ALLELE ANCESTRAL POSITION 
CONSERVATION 
SCORE 
CONSERVATION 
FOR GERP AND 
SIPHY 
rs12587 KRAS T/G G 12:25358828 0.111 YES 
rs10434 VEGFA A/G G 6:43753212 1.37 YES 
rs1126772 SPP1 A/G A 4:88904186 1.48 YES 
rs7973623 KRAS G/A G 12:25361074 1.64 YES 
rs3024496 IL10 A/G G 1:206941864 1.74 YES 
rs12211228 IRF4 G/C G 6:408833 2.78 YES 
Table 9. the best miRSNPs selected through the conservation parameter. 
 
 
3.6 –POWER CALCULATIONS 
 
One of the pivotal aspects of planning in this kind of study is the calculation of the sample 
size that will give a sufficient statistical power or alternatively, this is our case, calculate if 
our sample size, already collected, was sufficient to have an appreciable statistical power. 
 
It is a basic statistical principle with which we define if our sample size will be sufficient 
to minimize the risk of obtaining false positive or false negative results. The verification of 
an adequate sample size already collected, thus, becomes crucial in our epidemiological 
study and it is the process by which we can consider if our sample size will be able to 
arrive at an appreciable statistical power and, thus, arrive to scientifically valid results. For 
that purpose we have used a specialized algorithm called “Quanto” (version 1.2.4).  
 
We must consider some factors before calculating the final sample size: 
 Level of significance. Before starting a study we set an acceptable significance 
value. This value is the threshold to accept or refuse the null hypothesis, defined as: 
the allelic/genotypic distribution of our SNP is not different between cases and 
controls and, thus, the SNP is not associated with the disease. A different distribution 
might be due to chance.  
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If we refuse the null hypothesis then we will accept the alternative hypothesis, that 
associates our SNPs with a disease susceptibility. If the statistical analysis, in our 
samples, shows that the significance level is below the cut-off value we have set (e.g. 
p<0.05), we reject the null hypothesis and accept the alternative hypothesis. 
Alternatively, if the significance level is above the cut-off value, we accept the null 
hypothesis and refute the alternative hypothesis. 
Due to errors in inferences when we are carrying out case-control studies with more 
than one hypothesis, it is necessary to apply a correction for multiple testing to reduce 
the probability to have false positives. With this aim, several statistical techniques 
for correction have been developed. In our study we have chosen one of them, named 
Benjamini-Hochberg correction. Considering the significance level of 5% (α) and 
with the purpose of maintaining constant the familywise error rate (FWER), the 
Benjamini-Hochberg correction test each individual hypothesis (m) at a new 
significance level of [α(m+1)]/2m.  
Applying the Benjamini-Hochberg correction we set a lower threshold for 
significance value (0.03).  
 
 Power. The power or sensitivity of a binary hypothesis test is the probability that the 
test correctly rejects the null hypothesis (H0) when the alternative hypothesis (H1) is 
true. If this was not the case, we could go toward a bias called type II error.  
As the power increases, the chances of a type II error (false negative), which are 
referred to as the false negative rate (β), decrease, as the power is equal to 1−β. We 
set statistical power at least 80%. 
 
 Allele frequency. We set the allele frequencies range between 15% (that 
corresponding as the minor allele frequency of our miRSNPs) and 50%. 
 
 Risk that we expect to observe. Risks of developing disease in case-control studies 
are usually expressed as odds ratios (OR). Risks observed for SNPs as predictors of 
cancer are typically in the range of OR=1.1~2.0. 
 
We planned a study of cases and controls with 0.63 controls per case. In the current study 
we selected miRSNPs with a minor allele frequency (MAF) ≥ 0.15. With an allele 
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frequency of 0.15, in a recessive model with odds ratio equal to 1.7, we needed to study 
3.023 case patients and 1.905 control patients to be able to reject correctly the null 
hypothesis and accept the alternative hypothesis when this one is true with a probability 
(power) of 0.8. The Type I error probability associated with the test of this null hypothesis 
is 0.05. Since the available number of cases and controls is larger than the minimum 
required, we conclude that our study has sufficient statistical power to analyze the selected 
SNPs. 
 
 
3.7 – SAMPLE PREPARATION 
 
Genomic DNA had been previously extracted from peripheral blood or whole blood of 
MM cases and controls from each center participating in the IMMEnSE consortium. In 
order to ensure enough material for each genotyping project, a WGA (whole genome 
amplification) has been carried out on samples with low levels of DNA. The DNA stored 
had a minimum concentration of 10 ng/µl (the quantification was performed with 
Nanodrop spectrophotometer).  
All the genotyping assays were carried out in 384 well format, with 10 ng of DNA from 
each subject. The order of DNAs from cases and controls was randomized on plates in 
order to ensure that an equal number of cases and controls was analyzed simultaneously. 
For quality control purpose, duplicates of 10% of the samples were interspersed throughout 
the plates. 
 
 
3.7.1 – DNA EXTRACTION METHOD 
 
If the collaborators in IMMEnSE consortium provided us with blood samples we had to 
carry out a DNA extraction.  
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DNA extraction was conducted using QIAamp® 96 DNA QIAcube® HT Kit (Figure 4). 
This procedure yields high-quality DNA that performs well in PCR and other enzymatic 
reactions. The QIAmp 96 DNA QIAcube HT Kit combines the selective binding properties 
of silica-based membrane with a high-throughput 96-well format, and is designed for fully 
automated, simultaneous processing 96 blood samples of 200 µl in volume.  
Blood samples for processing could be fresh or frozen. Our samples had not been frozen 
and thawed more than once because yield and quality of the purified DNA depend on 
storage conditions of the blood.  
This DNA extraction procedure can be used for samples treated with citrate, heparin or 
EDTA. The fully automated procedure requires <2 hours to process 96 samples, with no 
hands-on time. 
Samples are first lysed using QIAGEN Proteinase K. Afterwards the lysate is loaded onto 
the QIAamp 96 plate and binding buffer (Buffer ACB) is added to provide optimal DNA 
binding conditions. During vacuum, DNA is selectively bound to the QIAamp membrane 
as contaminants pass through. Remaining contaminants and enzyme inhibitors are removed 
in three efficient wash steps with Buffer AW1, Buffer AW2, Ethanol. Pure DNA is eluted 
under vacuum in a single step in approximately 200 µl of Buffer AE and TopElute fluid 
equilibrated to room temperature (15–25°C).  
After that DNA is eluted in Buffer AE, it is free of proteins, nucleases, and other 
contaminants or inhibitors. It is ready for use in enzymatic reactions, such as PCR, or 
storage at -20°C. DNA purified using the QIAamp 96 DNA QIAcube HT Kit is up to 50 
kb in size, with fragments of approximately 20-30 kb predominating. DNA of this length 
denatures completely during thermal cycling and can be amplified very efficiently. 
 
Total volume of each reagent used for purification of genomic DNA from 96 whole blood 
cell samples (200 µl): 
 Buffer AW1, 64.6 ml. 
 Buffer AW2, 64.6 ml. 
 Ethanol 96%, 62.6 ml. 
 Buffer AE, 22.2 ml. 
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 Buffer ACB, 38.6 ml. 
 Buffer VXL (+ Proteinase K), 10.6 ml. 
 TopElute Fluid, 5.88 ml. 
 
 
 
Figure 4. Instrument for automated mid- to high-throughput nucleic acid purification in 96-well format. 
  
 
3.7.2 – QUANTIFICATION OF DNA 
 
Quantification of deoxyribonucleic acid was performed using a spectrophotometer named 
Nanodrop. The Nanodrop spectrophotometer uses a patented sample retention system 
(Figure 5) that holds 1 µl of sample without the need for traditional containment devices 
such as cuvettes and capillaries. 
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Figure 5. The Nanodrop Spectrophotometer microvolume sample retention system. (A) A sample volume of 
1 µl is dispensed onto the lower optical surface. (B) Once the instrument lever arm is lowered, the upper 
optical surface engages with the sample, forming a liquid column with the path length defined by the gap 
between the two optical surfaces.   
 
Using fiber optical technology and surface tension, the sample is held in place between two 
optical surfaces that define the pathlength in a vertical orientation. Direct coupling of the 
sample to the optics of the spectrophotometer removes interference caused by incident 
light and transmitted light passing through containment walls of the traditional cuvettes, 
microcell cuvettes, and capillaries. Preparation for the next sample only requires wiping of 
both optical surfaces with a common laboratory wipe. 
 
For quantifying, through NanoDrop, the DNA extracted from blood we followed this 
protocol: 
1. The upper and lower optical surfaces was cleaned by 1 µl or 2 µl of clean deionized 
water. 
2. Open the NanoDrop software and select the nucleic acids module. 
3. Initialize the spectrophotometer by placing 1 µl clean water onto the lower optic 
surface, lowering the lever arm, and selecting “initialize” in the NanoDrop software. 
Once initialization is complete (~ 10 sec), both optical surfaces have been cleaned. 
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4. Measuring the nucleic acid sample was performed by loading 1 µl and selecting 
“measure”. Once the measurement is complete, clean both optical surfaces.  
 
All measurements are automatically normalized to 340 nm. 
 
 
3.8 – GENOTYPING 
 
After DNA extraction and measurement of DNA concentration with the 
spectrophotometer, the DNA samples from cases and controls were randomly placed on 
plates where an equal number of cases and controls could be run simultaneously. 
Genotyping of the 6 selected miRSNPs was carried out by using the TaqMan Real Time 
PCR method in 384-well plates.  
For placing 10 ng of genomic DNA in each spot of 384-well was used a robot named 
Biomek® NXP Laboratory Automation Workstation (Beckman Coulter, Brea, USA).  
Two TaqMan probes were used, one for each allele. Analysis was performed using the 
ViiATM7 plate platform (Applied Biosystems®).  
The reaction employed the 5x HOT FIREPol qPCR Mix, TaqMan primers and probes 
(40x), water and 10 ng of DNA for total 5 µl of reaction.  
PCR reaction was performed using Hydrocycler 16 machine (Lcgenomics, Hoddesdon, 
UK) and the thermal cycle program used included one cycle at 95°C for 15 min to activate 
the Taq polymerase, 40 cycle at 95°C for 20 seconds to denature the DNA and at 60°C for 
1 minute for the stage of annealing/extension.  
The SDS Software, version 2.4 (Applied Biosystems®) was used to determine the 
genotypes. 
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3.8.1 - TaqMan REAL TIME PCR 
 
The Real-Time PCR also named quantitative PCR or real-time quantitative PCR (RTQ-
PCR) is a method of amplification and simultaneous quantification of DNA. 
The procedure follows the general principle of polymerase chain reaction. This variant of 
PCR always needs primers (reverse and forward), Taq polymerase and all other 
components normally employed in PCR.  
The key feature of this kind of PCR is that the amplified DNA is detected while the 
reaction progresses. For determining products in quantitative PCR, specific DNA probes 
consisting of oligonucleotides that are labelled with a fluorescent reporter (Figure 6) are 
commonly used, which permit detection only after hybridization of the probe with its 
complementary sequence to quantify the molecule that is being studied (DNA or RNA). 
 
 
FIGURE 6. How TaqMan Real-Time PCR work. 
 40 
 
Identification of polymorphic miRNA-binding sites associated with the risk of multiple myeloma 
 
The probe consists of two types of fluorophores: a fluorescent reporter at one end and a 
quencher of fluorescence at the opposite end of the probe. While the probe is attached or 
unattached to the template DNA and before the polymerase acts, the quencher (Q) 
fluorophore (usually a long-wavelength colored dye, such as red) reduces the fluorescence 
from the reporter (R) fluorophore (usually a short-wavelength colored dye, such as green). 
It does this by the use of Fluorescence Resonance Energy Transfer (FRET), which is the 
inhibition of one dye caused by another without emission of a proton.  
 
The reporter dye is found on the 5’ end of the probe and the quencher at the 3’ end. 
Once the TaqMan® probe has bound to its specific piece of the template DNA after 
denaturation (high temperature) and the reaction cools, the primers anneal to the DNA. Taq 
polymerase then adds nucleotides and removes the Taqman® probe from the template 
DNA thanks to exonuclease activity of the Taq polymerase. This separates the quencher 
from the reporter, and allows the reporter to emit its energy. This is then quantified using a 
computer. The more times the denaturing and annealing takes place, the more opportunities 
there are for the Taqman® probe to bind and, in turn, the more emitted light is detected so 
that an increase in the product targeted by the reporter probe at each PCR cycle therefore 
causes a proportional increase in fluorescence due to the breakdown of the probe and 
release of the reporter. 
 
 
3.8.2 – SNP GENOTYPING 
 
SNP genotyping is the measurement of genetic variations of single nucleotide 
polymorphisms (SNPs) between members of a specific species. The genotyping is a 
measurement of more general genetic variation. SNPs are one of the most common types 
of genetic variation. A SNP is a single base pair mutation at a specific locus, usually 
consisting of two alleles (where the rare allele frequency is >1%). SNPs are found to be 
involved in the etiology of many human diseases and are becoming of particular interest in 
pharmacogenetics. 
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TaqMan assay was used for performing the genotyping of our miRSNPs. During the PCR 
amplification step, if the allele-specific probe is perfectly complementary to the SNP allele, 
it will bind to the target DNA strand and then get degraded by exonuclease activity of the 
Taq polymerase as it extends the DNA from the PCR primers (Figure 7). The degradation 
of the probe products the separation of the fluorophores generating a detectable signal. If 
the allele-specific probe is not perfectly complementary to the target, the binding will form 
a mismatch. A mismatch along the binding between these two molecules causes the failure 
of the degradation of the probe. It will be removed intact by Taq polymerase, without the 
release of the report fluorophore. It is also important to emphasize that the fluorescence 
recorded is proportional to the quantity of amplified DNA in every moment of reaction, 
because a fluorophore is released for each copy of DNA duplicate.  
 
 
Figure 7. Application of TaqMan technology to SNP genotyping. 
 
For our study, TaqMan primers and probes mix was available as made-to-order or 
validated TaqMan SNP genotyping Assays (Life Technologies, Foster City, CA, USA). 
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Due to the unavailability of the probe rs7973623, we selected, through the computer 
program SNAP (http://www.broadinstitute.org/mpg/snap/), a new SNP that is nearly 
completely in linkage disequilibrium (LD) and is located at a distance of only 1.8 Kbp on 
the same chromosome. This new SNP is rs11047885 (Table 10). 
 
We chose an alternative SNP in LD with the first one because if two SNPs are in high LD 
(measured with the correlation coefficient r2, and defined in high LD with an arbitrary 
threshold of r2>0.9), they will be handed down together from generation to generation and 
provide essentially the same information. Thus if one of them has been found, in a case-
control study, associated with the disease, the other one will be, very likely, associated as 
well. 
 
ID GENE ALLELE ANCESTRAL POSITION R2 
rs11047885 CASC1 A/C A chr12:25342380 0.953 
Table 10. Details about the surrogate marker for rs7973623. 
 
PCR reactions were carried out using the 5x HOT FIREPol qPCR Mix.  
For each DNA sample (10 ng) the reaction mix was prepared as shown in the table:  
Reagents Volume 
5×Hot FirePol® qPCR Mix 0.83 µl 
40x TaqMan® SNP Genotyping Assay 0.063 µl 
Water 4 µl 
Total 5 µl 
 
The genotypes, for each sample, are provided considering the correlation between the 
emitted fluorescence and the corresponding allele (Figure 8): 
 A substantial increase in fluorescence VIC® indicates homozygosity for the first 
allele. 
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 A substantial increase of fluorescence FAM ™ indicates homozygosity for the 
second allele. 
 The emission of both signals indicates a condition of heterozygosity. 
 
 
Figure 8. An example of genotyping after the fluorescence reading with TaqMan assay. Cluster plots of 
SNPs: heterozygous (green), homozygous for the wild-type allele (blue), homozygous for the variant allele 
(red), undetermined (black crosses) and negative controls (black square). 
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3.9 – QUALITY CONTROL AND STATISTICAL ANALYSIS 
 
The quality of the genotype data was assessed on the basis of sample call rates (completion 
rates), concordance rates between duplicate DNAs (10%, usually are interspersed on 
plates), and deviation from Hardy-Weinberg equilibrium in the control groups. SNPs and 
samples classified unreliable by these indicators were removed from further analysis. 
To verify whether the genotypes were in Hardy-Weinberg equilibrium in controls for each 
specific population, we used the chi-square test with P = 0.025 as significance threshold 
previously corrected through Benjamini-Hochberg correction. Analysis of association 
between SNPs and MM risk was studied with multivariate logistic regression analysis 
(MLR) adjusting for a set of covariates that included the age (at diagnosis for MM cases, at 
recruitment for controls), gender and country of origin. The individual miRSNPs were 
input in the MLR analysis. The association between miRSNPs and MM risk was 
calculated, by estimating the odds ratio (OR) and its 95% confidence interval (C.I.), 
adjusted for covariates. For all genotypes, we performed initially a statistical analysis with 
the allelic model. After that the most significant miRSNPs according to the allelic model 
have been subjected to the others (dominant, additive and recessive model): 
 
 Allelic model. The allelic model is a genetic association analysis mode that 
examines the association between the disease and alleles. In the analysis, the wild-
type allele, assumed as reference category, is compared with the variant allele. 
 
 Dominant model. In classic genetics, dominance is the property possessed by some 
alleles of determining the phenotype by masking the effects of the other allele 
(when heterozygous). Dominant model is a genetic association analysis mode that 
examines the association with a dominant allele. The analysis consists of 
comparison between homozygous wild-type genotypes with the allele variant 
group (combining heterozygotes and homozygotes for the variant allele). 
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 Codominant genetic model. In codominant model the disease risk associated with 
AB individuals lies between that of AA (wild type homozygote) and BB 
individuals (minor allele homozygote), but not in specific relationship of an 
additive model. In the analysis, the homozygous wild-type, reference category, is 
compared separately with two different genotypes that lead the allele variant 
(heterozygotes and homozygotes for the variant allele). 
 Recessive model. A trait that is not expressed in heterozygotes but that can only be 
expressed in the homozygotes. The recessive model is a genetic association 
analysis mode that examines association with a recessive allele. The comparison 
groups are variant homozygous genotypes against the rest (combining 
heterozygotes for the variant and homozygotes for the wild-type allele). 
 
In all analyses we used the more common allele in the controls as reference category. The 
statistical threshold of significance was set at 0.05; however a correction for multiple 
testing was applied to reduce the higher probability to have false positive being in the 
presence of a study with more than one hypothesis. As Benjamini-Hochberg correction 
was applied to set a lower threshold of significance with the purpose of maintaining 
constant the false positive rate. In this case, because these 6 miRSNPs were not associated 
in LD and thus they were completely independent polymorphisms, the value of 6 was used 
to compute the Benjamini-Hochberg correction (P threshold = [0.05x(6x1)]/(2x6) = 3 x 10-
2). 
The MLR was performed with the help of the program STATA software (Stata Corp. LP, 
College Station, TX).  
 
 
3.9.1 – LOGISTIC REGRESSION ANALYSIS 
 
A statistical method for demonstrating that a risk factor is associated with the disease is the  
multivariate logistic regression analysis, adjusted for covariates in our possession (age, sex 
and geographic region). 
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The probability that the event will occur is given by: 
 
 
 
where x1, x2, ..., xi are the covariates included in the model and β1, β2, ..., βi its estimated 
coefficients and α is a constant. 
 
This formula is equivalent to the following, in which the effect of covariates is not 
associated with the probability of the event, but with the odd, the ratio between the 
probability of event and the probability of non-event. 
 
 
 
The second term of equality is called logit. The association between the logit and the 
explanatory variables is linear, in contrast with the previous formulation. 
Probability and odds are linked by the following relationship: 
 
 
 
In particular, the results derived from the logistic model are presented such as odds ratios 
(OR, odds ratio) and its confidence interval of 95% (95% CI). The OR is the relationship 
between the ratio of the probability of occurrence of cancer in patients with the variant 
genotype and the same ratio in patients with the common genotype. If the OR takes values 
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equal to 1, it means that the genotype does not influence the endpoint under consideration 
(in our case, the risk of developing MM), if the value is greater than 1 the genotype is a 
risk factor, if it is less than 1, the genotype is a protective factor. The confidence interval of 
the OR allows us to understand how accurately the OR was estimated (amplitude range) 
and to evaluate whether the test is statistically significant at the 5% level (which occurs if 
the 95% CI does not include 1).  
 
 
3.10 – PREDICTION OF GIBBS BINDING FREE ENERGY BETWEEN miRNA 
AND miRNA-BINDING SITES 
 
The most significant miRSNPs, after statistical analysis, were further evaluated for their 
capacity to affect the binding of the miRNAs, by assessing the variation of Gibbs free 
energy between the two alleles.  
This evaluation was carried out in silico by measuring the strength of binding both for the 
common and the variant alleles. The strength of binding was measured as the Gibbs 
binding free energy (ΔG, expressed in KJ/mol). Thus, the effect of genetic polymorphisms 
is measured as the difference of the free energies between the two alleles and computed as 
“variation of ΔG” (i.e. ΔΔG). Because all miRSNPs analyzed are predicted to bind several 
miRNAs, and thus, these polymorphisms could impact the binding site of more than one 
miRNA, we used the sum of all |ΔΔG| for each miRSNP (|ΔΔGtot|) that is the sum of the 
difference of the free energies between the two alleles, of such polymorphisms, and each 
putative miRNA that binding them. |ΔΔGtot| was used as parameter for predicting the 
biological impact of the polymorphisms.  
Even though each miRNA-binding site can bind only one miRNA at the same time in each 
tissue, this approach is based on the basic idea that the more miRNAs are predicted to bind 
to a given target, the more it is likely that at least one of them truly binds to the target. 
Thus, if the algorithms predict that only one miRNA binds to a given target, at least in 
theory, we should consider this target less important than others predicted to bind many 
different miRNAs. 
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First of all, to perform the prediction of binding we selected the set of miRNAs that bind 
the most significant miRSNPs which result from statistical analysis. For this purpose we 
conducted a search using a series of online tools as miRBase (http://www.mirbase.org/), 
TargetScan (http://www.targetscan.org/) and Diana-Micro-T 
(http://diana.cslab.ece.ntua.gr/microT/). 
 
Afterwards the strength of binding of miRNAs with the wild-type and variant allele of such 
polymorphisms was performed by miRanda. Such algorithm calculated the strength of 
binding considering: 
 the sequence complementarity between the mature miRNA and the target site.  
 the binding energy of the miRNA-target duplex. 
 the evolutionary conservation of the target position in aligned UTRs of homologous 
genes. 
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4. RESULTS 
 
We checked for statistically significant deviations from the Hardy-Weinberg equilibrium in 
controls, dividing them by country of origin. Deviations from the Hardy-Weinberg 
equilibrium were not observed for all SNPs with the exception of Danish samples where 
was observed a significant deviation from Hardy-Weinberg equilibrium for rs12211228, 
rs11047885, rs1126772, rs12587. Therefore for these 4 SNPs we excluded Danish subjects 
from all further statistical analyses. 
The mean call rate of SNP genotyping was 91.92% and was uniform between cases and 
controls. Concordance of genotypes between duplicate samples was 98.13%. 
The main effects of the genetic polymorphisms on MM were assessed by unconditional 
logistic regression adjusted for age, gender and region of origin. Details of distribution of 
genotypes are shown in Table 11. 
 
SNP GENOTYPE 
CASES 
N (%) 
CONTROLS 
N (%) 
rs12587 
GG 
940 
(31.97) 
432 
(30.4) 
CG 
1365 
(46.43) 
707 
(49.75) 
CC 
635 
(21.6) 
282 
(19.85) 
rs10434 
G/G 
978 
(32.01) 
575 
(29.98) 
A/G 
1471 
(48.15) 
959 
(50) 
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A/A 
606 
(19.84) 
384 
(20.02) 
Table 11. Distribution of genotypes between patients. 
 
The age distributions (Figure 9) between the samples showed differences median ages 
between controls (median age = 52) and cases (median age = 62). The lower median age in 
controls group is due to the fact that a high number of control samples were collected from 
blood donors that, typically, have a lower age than multiple myeloma patients. 
 
 
rs1126772 
A/A 
1846 
(61.68) 
877 
(60.99) 
A/G 
1004 
(33.54) 
494 
(34.35) 
G/G 
143 
(4.78) 
67 
(4.66) 
rs11047885 
A/A 
1895 
(63.48) 
941 
(65.57) 
A/C 
963 
(32.26) 
439 
(30.59) 
C/C 
127 
(4.25) 
55 
(3.83) 
rs3024496 
GG 
562 
(18.78) 
424 
(22.58) 
AG 
1451 
(48.48) 
879 
(46.81) 
AA 
980 
(32.74) 
575 
(30.62) 
rs12211228 
GG 
2299 
(74.96) 
1051 
(72.43) 
CG 
705 
(22.99) 
365 
(25.16) 
CC 
63 
(2.05) 
35 
(2.41) 
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Figure 9. Age distributions of samples. 
 
Analysing the results we observed the association between MM risk and the age (P- value 
= 0.0001). This result is in line with the dynamic of occurrence of such neoplastic disease 
due to the fact that it normally affects older persons. 
 
Moreover, we observed as well the association between MM risk and the country of origin 
(P-value < 0.001). This result would make us conclude that some regions had higher 
incidence of MM than the other ones. Instead, this observation is only an artifact because 
within the IMMEnSE consortium cases and controls were collected with different ratio 
between regions.  
As, for example, Polish samples analysed in this case-control study counted 350 controls 
and 1.259 cases (see Table 5). Such huge different ratio between cases and controls could 
lead to thought, during statistical analysis, that in Poland MM risk is higher than the rest of 
Europe but we know thanks to incidence data collected through cancer registries that it is 
not true. 
 
 
4.1 – ALLELIC MODEL ANALYSIS 
 
As previously mentioned, we have started the statistical analysis with the allelic model 
adjusted for sex, age and region to find association between these 6 miRSNPs selected and 
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MM risk cancer. After that, the most promising SNPs were further analysed with 
dominant, codominant and recessive model. For all these model we have applied the 
Benjamini-Hochberg correction for multiple testing, the new lower threshold for the 
statistical significance became 0.03.   
 
The first polymorphism rs12211228, in IRF4 gene, has not shown any association with 
MM risk (Table 12). But it is important to underline anyway that the variant allele C has a 
p-value (P = 0.036) very near the significance threshold. Otherwise, the allelic model 
adjusted with covariates for rs11047885, rs1126772, rs10434, rs12587 did not show any 
association between the polymorphism and MM cancer risk, considering as the reference 
category the wild-type allele. 
 
SNP ALLELES OR 95% C.I. p-value 
rs12211228 
G 1.00 Ref - 
C 0.87 0.76 – 0.99 0.036 
rs11047885 
A 1.00 Ref - 
C 1.05 0.93 – 1.18 0.441 
rs1126772 
A 1.00 Ref - 
G 1.00 0.90 – 1.13 0.87 
rs10434 
G 1.00 Ref - 
A 0.99 0.91 – 1.09 0.90 
rs12587 
G 1.00 Ref - 
T 0.98 0.89 – 1.07 0.62 
Table 12. Allelic model for rs12211228, rs1126772, rs10434, rs12587 adjusted with sex, age and region. 
 
The association between these miRSNPs and MM risk was found in rs3024496, within 
IL10, for the variant allele A (p-value = 0.29) in adjusted allelic model. It has been 
associated with an increased risk of MM (OR = 1.05; 95% C.I = 0.96 – 1.15) considering 
as the reference category the wild-type allele G. More details in Table 13.  
 
ALLELES OR 95% C.I. p-value 
G 1.00 Ref - 
A 1.05 0.96 – 1.15 0.29 
Table 13. Allelic model for rs3024496 adjusted with sex, age and region. 
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4.2 – DOMINANT, CODOMINANT AND RECESSIVE MODEL 
 
Further analysis for rs12211228 and rs3024496 have unveiled that a single miRSNP was 
associated with MM risk in unadjusted codominant and dominant model, this miRSNP is 
rs3024496. In co-dominant model unadjusted for covariates, both the heterozygotes AG 
(P-value = 0.004) and homozygotes AA (P-value = 0.002) were associated with an 
increased risk of MM (OR = 1.24; 95% C.I.= 1.07 – 1.45 and OR = 1.28; 95% C.I. = 1.09 
– 1.51, respectively) considering the genotype GG as the reference category. Moreover a 
statistically significant trend was observed both for unadjusted data (P-value  = 0.0047) 
and adjusted data (P-value = 0.0078). Moreover, the second strongest association was 
always observed in rs3024496 for the allele A (P-value = 0.001) in unadjusted dominant 
model, with an almost 1.3-fold increased risk for the A allele (odds ratio [OR] = 1.26, 95% 
confidence interval [C.I.]: 1.09 – 1.45). Details of statistical analysis are reported in Table 
14. 
 
SNP GENOTYPES OR 95% C.I. p-value 
rs3024496 
GG 1.00 Ref - 
AG 1.24 1.07 – 1.45 0.004 
AA 1.28 1.09 – 1.51 0.002 
rs3024496 
GG 1.00 Ref - 
AA + AG 1.26 1.09 – 1.45 0.001 
Table 14. Codominant and dominant unadjusted model for rs3024496. 
 
However, considering adjusted co-dominant and dominant model the findings did not show 
any association between the polymorphism and MM cancer risk. More details about that 
are reported Table 15. 
 
SNP GENOTYPES OR* 95% C.I. p-value 
rs3024496 
GG 1.00 Ref - 
AG 1.11 0.94 – 1.31 0.219 
AA 1.11 0.93 – 1.33 0.254 
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rs3024496 
GG 1.00 Ref - 
AA + AG 1.11 0.95 – 1.30 0.191 
Table 15. Co-dominant and dominant adjusted model for covariates about rs3024496. 
*ORs are adjusted for age, gender and region. 
 
The unadjusted and adjusted recessive model for rs3024496 did not show any association 
with the disease (Table 16). 
 
SNP GENOTYPES OR 95% C.I. p-value 
rs3024496 
GG + AG 1.00 Ref - 
AA 1.10 0.97 – 1.25 0.122 
rs3024496 GG + AG 1.00 Ref - 
 AA 1.03 0.90 – 1.18 0.658 
Table 16. Recessive unadjusted and adjusted model for rs3024496. 
 
Regarding the miRSNP rs12211228, none of the analyses highlighted significant p-values 
(Table 17-19). 
 
SNP GENOTYPES OR 95% C.I. p-value 
rs12211228 
GG 1.00 Ref - 
CG 0.88 0.76 – 1.02 0.087 
CC 0.82 0.54 – 1.25 0.362 
rs12211228 
GG 1.00 Ref - 
CG 0.88 0.75 – 1.02 0.102 
CC 0.73 0.47 – 1.14 0.169 
Table 17. Co-dominant unadjusted and adjusted model for rs12211228. 
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SNP GENOTYPES OR 95% C.I. p-value 
rs12211228 
GG 1.00 Ref - 
CG + CC 0.87 0.76 - 1.01 0.065 
rs12211228 
GG 1.00 Ref - 
CG + CC 0.86 0.74 – 1.00 0.058 
Table 18. Dominant unadjusted and adjusted model for rs12211228. 
 
SNP GENOTYPES OR 95% C.I. p-value 
rs12211228 
GG + CG 1.00 Ref - 
CC 0.85 0.56 – 1.29 0.443 
rs12211228 GG + CG 1.00 Ref - 
 CC 0.75 0.49 – 1.17 0.215 
Table 19. Recessive unadjusted and adjusted model for rs12211228. 
 
 
4.3 - BINDING ENERGY PREDICTION BETWEEN rs3024496 AND miRNAs 
 
rs3024496 showed a high |ΔΔGtot| (table 20). In particular, in this miRSNP a significant 
variation can be highlighted regarding the ΔΔG of miR-125a-3p and miR-202-3p where 
the presence of the variant allele is predicted to be associated with a tighter binding. This 
means that such polymorphism may influence the IL10 gene expression through regulation 
by miRNAs.  
 
Gene dbSNP ID miRNA 
Allele WT/ ΔG allele 
WT 
Allele variant/ ΔG 
allele variant  
ΔΔG |ΔΔGtot| 
IL10 rs3024496 
let-7d-5p 
miR-125a-3p 
miR-17-3p 
miR-202-3p 
miR-140-5p 
 
G/  -17.52 
G/ -18.61 
G/ -14.24 
G/ -17.87 
G/ -14.05 
A/ -18.47 
A/ -16.24 
A/ -14.24 
A/ -13.99 
A/ -13.99 
0.95 
-2.37 
0 
-3.88 
-0.06 
 
7.26 
 
Table 20. Evaluation of SNP rs3024496 for binding energy prediction with the miRNAs. 
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5. DISCUSSION 
 
In the present study, one polymorphisms (rs3024496 in IL10) was found associated with an 
increased risk of MM. Five different miRNAs are predicted to bind within IL10: let-7d-5p, 
miR-125a-3p, miR-17-3p, miR-202-3p, miR-140-5p (see Table 20). When A substitutes 
G, miR-202-3p and miR-125a-3p are predicted to bind more tightly to the IL10 3’UTR. In 
contrast let-7d-5p decreased its binding affinity, while miR-17-3p and miR-140-5p do not 
show any variation of binding with mRNA. It should be underlined that let-7d (the family 
to which let-7d-5p belongs) was shown to be present in normal plasma cells, and its 
expression appeared to be reduced in MM so much that it can be considered as biomarker 
for multiple myeloma as result of measurements done with TaqMan Low Density Arrays 
and quantitative real-time PCR in the serum of multiple myeloma patients and healthy 
donors [83]. 
Emerging evidence has suggested that miR-125a-3p, which plays a role as tumor 
suppressor, is epigenetically silenced in MM [84]. Instead, miR-17-3p was found 
upregulated in MM but not in MGUS and normal plasma cells [85]. 
Change in expression for miR-140 is thought to be involved in myelomagenesis and it is 
also associated with overall prognosis [86]. 
Interleukin (IL10) is a pleiotropic, immunoregulatory cytokine that is important in 
protecting the host from infection-associated immunopathology, autoimmunity and allergy. 
IL-10 was initially characterized as a T helper (TH)2 specific cytokine 
[87]; however, further 
investigations revealed that IL-10 production was also associated with T regulatory (Treg) 
cell responses. It is now known that almost all cells of both the innate and adaptive arms of 
the immune system can express IL-10, including dendritic cells (DC), macrophages, mast 
cells, natural killer cells (NK), eosinophils, neu-trophils, B cells, CD8+ T cells, and TH1, 
TH2, and TH17 CD4
+ T cells [88-98].  IL-10 can significantly enhance the proliferation of B 
cells, being involved in their terminal differentiation into plasma cells [99]. 
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IL-10 has been implicated in the pathogenesis of other malignant B-cell neoplasmas 
[100,101], such as chronic lymphocytic leukemia and diffuse large B-cell lymphoma, where 
its serum levels in untreated patients are increased and have been correlated with an 
inferior survival [102]. Thus, IL-10 may be involved at different steps of B lineage 
expansion and differentiation. Furthermore, it seems to act as a growth factor for MM cells 
[103]. Increased serum levels of IL-10 have been associated with advanced MM stage [104]. 
Moreover, Liu et al. showed that MM cells produced multiple inhibitory cytokines of 
osteoclastogenesis, such as IL-10, which activated STAT3 signaling and induce OC 
inhibition [105]. 
It is also well know that IL-10 acts as chemoattractan for macrophages in tumor 
microenvironment, after being released from cancer cells. In oncology, in fact, tumor-
associated macrophages (TAMs) coordinate various aspects of the malignancy, such as 
tumor growth and progression, angiogenesis, metastasis, immunosuppression and tissue 
remodelling [106,107]. Since TAMs are accumulated in hypoxic areas of tumors, when they 
get activated they acquire the ability to secrete various pro-angiogenic mediators 
(including growth factors, cytokines, proteases and chemokines) in order to promote 
angiogenesis and to influence tumor growth [108-111]. It seems that IL-10 and hypoxia have a 
synergistic role to influence macrophage function and angiogenemic homeostasis, 
suggesting that the pro-angiogenic effects of hypoxic macrophages are IL-10-dependent 
and require IL-10 mediated signal transduction [111]. IL-10 can also be regarded as an anti-
inflammatory, immunosuppressive cytokine, that favors tumor escape from immune 
surveillance. Thus, the autocrine circuit of TAM-derived IL-10 may suppress the 
expression of the potential antitumor IL-12 [107]. 
Through measurements done with ELISA in the serum of 54 multiple myeloma patients 
and 20 healthy donors, Alexandrakis et al. confirmed higher serum levels of IL-10 in MM 
patients compared to controls and moreover, increased in advanced disease [112] . They also 
confirmed a significant increase for markers of proliferation in MM patients (BAFF serum 
levels and BM infiltration) and markers of angiogenesis (VEGF and Ang-2 serum levels) 
in parallel with disease progression.  
Nevertheless, IL-10 also possesses some immunostimulating properties which makes it 
questionable to merely categorize this cytokine as a target of anti-immune escape 
therapeutic strategies or rather, as an immunological adjuvant in the fight against cancer 
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[113-115]. All the above information suggests the controversial role of IL-10 in tumor 
microenvironment. 
Knowing that the expression of miR-125a-3p is lower in MM cells than healthy controls 
[84], and considering that such miRNA together with miR-202-3p bind less tightly the IL-10 
mRNA in presence of the variant allele on rs3024496 (see Table 20). We can affirm that 
miR-125a-3p and miR-202-3p are two of the key molecules involved in myelomagenesis 
and the variant allele of rs3024496 could contribute, as our results suggest, to favor the 
increased levels of IL-10 and, ultimately, to favor the development of MM with an 
increased proliferation of B cell and an increased angiogenesis in tumor microenvironment. 
However, our results can also support the hypothesis that a lower IL-10 level could 
contribute with the myelomagenesis as well, leading to reduced immune response and 
playing an important role for the modulation of the individual risk. If we assume the role 
let-7d-5p that binds more tightly the miRNA-binding sites, one could speculate that the 
variant allele of rs3024496 is linked to decreased levels of IL10, thereby favouring a 
decline of the immune response predisposing to MM. 
Even though these SNPs showed a statistically significant association with MM, none of 
them showed a very significant p-value taking into account the correction for multiple 
testing. The only significant findings were obtained with analyses not adjusted for 
covariates (age, sex, region). Thus, the association we found between a SNP in IL10 and 
MM risk could still reflect a chance finding.  
This study has some strengths: i) an adequate sample size and ii) the prioritization of 
candidate genes was carried out according to functional criteria. The bioinformatic 
approach was made with more than one algorithm with the aim to reduce the artifacts risk 
caused by the uncertainty related to the reliability for every single algorithm. The ranking 
miRSNPs was done with conservation criteria. The meaning of conservation parameter is 
that if one nucleotide is very conserved inside a specific gene (on miRNA-binding sites, in 
our case) along the evolution it should be very important for the good function of the 
correlated protein and, in the last analysis, for the whole cell. 
At the same time, the current study has some weaknesses: i) arbitrary criteria have been 
followed for the selection of the candidate genes. The pathways chosen for our research are 
clearly important in MM but, on the other hand, other pathways that have not been 
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included could be important as well. ii) The predictions of binding were carried out only 
with in silico tools, and not experimentally confirmed. 
In conclusion, we have analyzed 52 MM-related genes and selected, with in silico 
methods, six SNPs predicted to have an impact on miRNA binding. One of them was 
associated with MM risk after Benjamini-Hochberg correction. This study provides 
evidence that this SNP in miRNA-binding sites may be important to cancer risk and 
supports future work to validate the results in other well-characterized populations as well 
as to explore the biological significance of these particular SNPs. The proposed approach 
could ease the identification of functionally relevant polymorphisms involved in cancer 
genesis to be further analyzed by appropriate experiments of molecular biology. 
Further work is needed to clearly establish the mechanisms of MM pathogenesis and to 
discover new potential targets for MM therapies. For this aim, it could be useful to 
extended the search of SNPs that affect miRNA binding to the entire genome, using 
appropriate in silico tools. Another line of research could be the use of already existing 
data from genome-wide association studies (GWAS), that could help us to validate the 
miRSNPs selected in this work and conduct a meta-analysis to combine these results. At 
the same time, it is important to carry out functional assays with the aim to understand 
better the possible role of rs3024496 in MM etiopathogenesis. 
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